What is the success rate of afatinib in treating lung cancer?

Afatinib is an irreversible tyrosine kinase inhibitor ( TKI), specifically targeted at EGFR mutation-positive non-small cell lung cancer (NSCLC) patients . As a second-generation EGFR-targeted drug, afatinib achieves anti-cancer effects by simultaneously inhibiting multiple receptors of the ErbB family (including EGFR, HER2 and ErbB4). Compared with first-generation targeted drugs such as gefitinib or erlotinib, afatinib has shown better disease control capabilities in certain rare EGFR mutations, especially non-classical mutations such as G719X, L861Q and S768I, which have shown better therapeutic responses. This makes afatinib the drug of choice in individual EGFR mutation subtypes.

However,"Success rate" is not a standard medical evaluation term. In clinical practice, "remission rate", "progression-free survival (PFS)" and "overall survival (OS)" are more commonly used to measure drug efficacy. According to current treatment practices, afatinib can bring relatively stable disease control to patients with newly treated EGFR-sensitive mutations, and some patients can achieve progression-free survival of more than 1 year after treatment. It is worth noting that the success of afatinib treatment is also affected by multiple factors such as patient mutation type, medication compliance, comorbidities, and tumor burden. Therefore, although "success rate" percentages cannot be generalized, afatinib does provide significant benefit for targeted therapy in certain populations.

In general, afatinib is one of the effective treatments for EGFR mutated lung cancer. Under the trend of precision medicine, afatinib plays an irreplaceable role in clinical application due to its ability to cover multiple EGFR mutations and its strong target binding ability. Future combination regimens with immunotherapy or anti-angiogenic drugs may further enhance the efficacy prospects of afatinib.

Reference materials:https://www.giotrif.com/